Saturday, October 10, 2015 12:52:58 PM
Welcome everybody on the board, be long or short. Ignore the bullying by grumpy, old man who has a huge ego, but sensitive as a little girl. The world is more than US or than science. All opinion are welcomed IF has some factual background.
A sort summary of my view:
GIA:
> It was the right (possible) choice in 2012, when nobody would like to pay the real value (especially ahead of ABCHOR approval)
> It will be the worst scenario - both for the company and both for investors - after successful R-IT, but I do not think it will happen
script#:
> Nothing is wrong w it. Meanwhile double the # within 6 months isn't a most likely scenario it is possible. We will see the effect of "open" label communication during the upcoming quarters and we will see the coverage by Q1.
> Mog- Hey, I made a call. Do you stand your bet?
> no new US partnership / sales force extension before R-IT interim
legal:
> all cases are heading to the right solution
- Class Action: dismiss
- 1A: settlement / joint letter
- NCE: granted (for 2012-2017 ...)
- ANDA: dismiss
financial / dilution:
> definitely no dilution / new cash is necessary before interim read-out
> if R-IT won't be stopped new cash could be necessary. (Please note: we do not know what will be the scrpt# @ that time / when next payment due for China / when next ex-US deal will be signed)
Meanwhile I would like to see a higher PPS (and it could be higher), it is irrelevant, since any higher PPS will be significantly lower than the PPS in case of early stop of R-IT.
R-IT:
> it won't be stopped before interim (everything is possible, but any other suggestion is a pure BS)
> no guarantee for early stop (top of the number, the DMC could take into account the "landscape")
> Assuming the Company's projection is correct (interim / final - 2016 / 2017) the 967th event could be in Q1 only.
> Based on available info, the chance of early stop isn't bad
Overall, we will know much more after the next CC.
Best,
G
A sort summary of my view:
GIA:
> It was the right (possible) choice in 2012, when nobody would like to pay the real value (especially ahead of ABCHOR approval)
> It will be the worst scenario - both for the company and both for investors - after successful R-IT, but I do not think it will happen
script#:
> Nothing is wrong w it. Meanwhile double the # within 6 months isn't a most likely scenario it is possible. We will see the effect of "open" label communication during the upcoming quarters and we will see the coverage by Q1.
> Mog- Hey, I made a call. Do you stand your bet?
> no new US partnership / sales force extension before R-IT interim
legal:
> all cases are heading to the right solution
- Class Action: dismiss
- 1A: settlement / joint letter
- NCE: granted (for 2012-2017 ...)
- ANDA: dismiss
financial / dilution:
> definitely no dilution / new cash is necessary before interim read-out
> if R-IT won't be stopped new cash could be necessary. (Please note: we do not know what will be the scrpt# @ that time / when next payment due for China / when next ex-US deal will be signed)
Meanwhile I would like to see a higher PPS (and it could be higher), it is irrelevant, since any higher PPS will be significantly lower than the PPS in case of early stop of R-IT.
R-IT:
> it won't be stopped before interim (everything is possible, but any other suggestion is a pure BS)
> no guarantee for early stop (top of the number, the DMC could take into account the "landscape")
> Assuming the Company's projection is correct (interim / final - 2016 / 2017) the 967th event could be in Q1 only.
> Based on available info, the chance of early stop isn't bad
Overall, we will know much more after the next CC.
Best,
G
#STRONGERTOGETHER
Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
